Hoya Vision Care expands MiYOSMART spectacle lens power range to offer broader range of negative and cylindrical powers

News
Article

The extension includes lenses that range from minus power of -13.00 diopters to cylindrical power up to 4.00 diopters

An optometrist hands a paediatric patient her new glasses. Image credit: ©Yakobchuk Olena – stock.adobe.com

Slowing down the progression of myopia by just one diopter can reduce the risk of myopic maculopathy by 40%, research findings indicate. Image credit: ©Yakobchuk Olena – stock.adobe.com

Hoya Vision Care is expanding the power range of their MiYOSMART spectacle, now offering a broader range of negative and cylindrical powers to help more patients with high myopia manage the condition. The expanded range of lenses also feature slimmer edge thickness than previous iterations, and the larger diameter works with a wider selection of frames.1

The extension includes lenses that range from minus power of -13.00 diopters (D) to cylindrical power up to 4.00 D, accommodating both high myopia and astigmatism. The goal is to increase access to effective solutions for myopic children across the globe for improved visual outcomes.

“There is an urgent need to provide comprehensive solutions for children with high myopia as early as possible in order to reduce the risk of myopia-related complications in later life,” Natalia Vlasak, MD, MBA, Global Head of Medical and Scientific Affairs at HOYA Vision Care, said in a press release. “Slowing down the progression of myopia by just one diopter can reduce the risk of myopic maculopathy by 40%.2 With the extension of MiYOSMART’s power range to treat high myopia, it is not too late for these children to preserve their vision health for the future.”

Myopia is an epidemic, and high myopia carries extra risks, including increased incidence of myopic macular degeneration, retinal detachment, cataract, open angle glaucoma, vision loss and additional complications associated with axial lengthening.3 While there is no treatment for myopia, it can be managed by slowing axial lengthening, typically via use of contact lenses or atropine drops.

"With the power range extension of MiYOSMART spectacle lenses to support children with high myopia, we are ensuring that it is never too late to help protect their vision for the future," said Vlasak in an exclusive quote. "Expanding access to MiYOSMART spectacle lenses to treat high myopia is a testament to HOYA's pledge to preserve the vision health of all children. We are dedicated to empowering Eye Care Professionals, parents, and policymakers to take urgent action for children’s eye health—continuously enhancing our myopia management solutions worldwide while advocating for vision-friendly habits, such as spending more time outdoors."

MiYOSMART is available in select countries, with wide availability in Europe and Canada. The US FDA granted Breakthrough Device designation to SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lenses in February 2024,4 but the agency has not approved additional spectacle options for myopia management.

MiYOSMART spectacle lenses launched in 2018, and more than 10 million units have been purchased across 40 countries.1 Hoya Vision Care is dedicated to innovative solutions for myopia management that not only limit the progression of the disease, but they also hope encourage wear time in patients to limit myopia progression effectively. By increasing lens diameter to fit more frames and decreasing edge thickness, Hoya has improved the cosmetics of their lenses to head off concerns about the look of conventional high prescription lenses.

Hoya Vision Care plans to continue to evolve treatment solutions to improve access to effective and innovative myopia control tactics, according to a news release.

References

1. HOYA Vision Care responds to the growing global issue of high myopia with new solutions to preserve children’s vision health. Hoya Vision Care. Press release. January 23, 2025. Accessed January 23, 2025. https://www.hoyavision.com/about-hoya/hoya-vision-care-news/news/hoya-vision-care-responds-to-the-growing-global-issue-of-high-myopia-with-new-solutions-to-preserve-childrens-vision-health/
2. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci. 2019 Jun;96(6):463-465. doi: 10.1097/OPX.0000000000001367. PMID: 31116165.​
3. Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The Complications of Myopia: A Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49. doi:10.1167/iovs.61.4.49
4. Maharjan EK. FDA grants SightGlass Vision Breakthrough Device designation for DOT spectacle lenses. Optometry Times. February 15, 2024. Accessed January 23, 2025. https://www.optometrytimes.com/view/fda-grants-sightglass-vision-breakthrough-device-designation-for-dot-spectacle-lenses
Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.